The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| GNGBF | +17.55% | -2.68% | -0.54% | +109% |
| S&P | +14.43% | +77.25% | +12.13% | +542% |
Getinge AB is a medical technology company specializes in providing equipment, systems, operating rooms, intensive-care units to the healthcare and the life science industries. It offers products and solutions for intensive care, cardiovascular procedures, operating rooms, sterile reprocessing and life science. The firm operates through the following segments: Acute Care Therapies, Life Science and Surgical Workflows. The Acute Care Therapies segment offers solutions for life support in acute health conditions. The Life Science segment offers a comprehensive range of equipment, technical expertise and consultation to prevent contamination in biopharmaceutical production, biomedical research, medical device manufacturing and laboratory applications. The Surgical Workflows segment offers products and services for efficient disinfection and sterilization of instruments used in operations, operating tables and other high-quality hardware for operating rooms and advanced IT systems for efficient and secure hospital workflows. The company was founded by Olander Larsson in 1904 and is headquartered in Gothenburg, Sweden.
No news articles found for Getinge Ab (publ).
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $1.08B | 5.4% |
| Gross Profit | $478.06M | 9.7% |
| Gross Margin | 44.15% | 1.7% |
| Market Cap | $6.02B | 41.5% |
| Market Cap / Employee | $515.80K | 43.0% |
| Employees | 11.7K | -1.0% |
| Net Income | $92.38M | 49.1% |
| EBITDA | $223.67M | 6.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $368.92M | 38.9% |
| Accounts Receivable | $627.20M | -4.7% |
| Inventory | 652.8 | 9.5% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $967.80M | 29.1% |
| Short Term Debt | $212.83M | -3.9% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 3.87% | 1.2% |
| Return On Invested Capital | 7.83% | 0.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $127.77M | -15.6% |
| Operating Free Cash Flow | $168.27M | -7.1% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 42.44 | 37.62 | 28.83 | 27.62 | -5.01% |
| Price to Book | 1.92 | 1.69 | 1.89 | 1.94 | 36.15% |
| Price to Sales | 1.75 | 1.59 | 1.66 | 1.81 | 32.46% |
| Price to Tangible Book Value | -10.19 | -9.47 | -9.29 | -10.79 | 64.29% |
| Price to Free Cash Flow TTM | 50.35 | 42.23 | 33.32 | 43.97 | 88.66% |
| Enterprise Value to EBITDA | 44.64 | 41.14 | 42.65 | 32.56 | 31.30% |
| Free Cash Flow Yield | 2.0% | 2.4% | 3.0% | 2.3% | -46.99% |
| Return on Equity | 4.5% | 4.8% | 6.7% | 7.6% | 47.24% |
| Total Debt | $1.14B | $1.17B | $1.22B | $1.18B | 21.61% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
